Tepoditamab (MCLA-117) 是一种双特异性的单克隆抗体，可以与骨髓细胞的CLEC12A和细胞毒性T细胞的CD3结合。其中，CLEC12A 是一种骨髓分化抗原。Tepoditamab (MCLA-117) 可以杀死 AML 白血病母细胞和 AML 白血病干细胞，诱导 T 细胞介导的急性髓细胞增殖裂解，可用于急性骨髓性白血病（AML）研究。
| 生物活性 | Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds toCLEC12Aof myeloid cells andCD3of cytotoxic T cells. Amongothers, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research[1]. |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
